{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:20:56Z","timestamp":1790839256701,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG-17475"],"award-info":[{"award-number":["IG-17475"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MCO9998 as group leader"],"award-info":[{"award-number":["MCO9998 as group leader"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF 2016-02363995"],"award-info":[{"award-number":["RF 2016-02363995"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5 x 1000 Funds\u20142013"],"award-info":[{"award-number":["5 x 1000 Funds\u20142013"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004008","name":"Istituto Superiore di Sanit\u00e0","doi-asserted-by":"publisher","award":["ISS-13ONC\/5"],"award-info":[{"award-number":["ISS-13ONC\/5"]}],"id":[{"id":"10.13039\/501100004008","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Choline kinase-\u03b1 (ChoK\u03b1\/\n                      <jats:italic>CHKA<\/jats:italic>\n                      ) overexpression and hyper-activation sustain altered choline metabolism conferring the\n                      <jats:italic>cholinic phenotype<\/jats:italic>\n                      to epithelial ovarian cancer (OC), the most lethal gynecological tumor. We previously proved that\n                      <jats:italic>CHKA<\/jats:italic>\n                      down-modulation reduced OC cell aggressiveness and increased sensitivity to in vitro chemotherapeutics\u2019 treatment also affecting intracellular content of one-carbon metabolites. In tumor types other than ovary, methionine decrease was shown to increase sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor 2 triggering. These effects were suggestive of a potential role for ChoK\u03b1 in regulating susceptibility to TRAIL cytokine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The relationship between ChoK\u03b1\/\n                      <jats:italic>CHKA<\/jats:italic>\n                      and TRAIL-receptor 2 (TRAIL-R2) expression was investigated in silico in OC patients\u2019 GEO datasets and in vitro in a panel of OC cell lines upon transient\n                      <jats:italic>CHKA<\/jats:italic>\n                      silencing (siCHKA). The effect of siCHKA on metabolites content was assessed by LC-MS. The triggered apoptotic signalling was studied following soluble-TRAIL or anti-TRAIL-R2 agonist antibody treatment. Lipid rafts were isolated by Triton X-100 fractionation. Preclinical ex vivo studies were performed in OC cells derived from patients\u2019 ascites using autologous PBLs as effectors and a bispecific anti-TRAIL-R2\/anti-CD3 antibody as triggering agent.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we demonstrate that siCHKA specifically overcomes resistance to TRAIL-mediated apoptosis in OC cells. Upon siCHKA we detected: a significant sensitization to caspase-dependent apoptosis triggered by both soluble TRAIL and anti-TRAIL-R2 agonist antibody, a specific increase of TRAIL-R2 expression and TRAIL-R2 relocation into lipid rafts. In siCHKA-OC cells the acquired TRAIL sensitivity was completely reverted upon recovery of ChoK\u03b1 expression but, at variance of other tumor cell types, TRAIL sensitivity was not efficiently phenocopied by methionine deprivation. Of note, we were also able to show that siCHKA sensitized tumor cells derived ex vivo from OC patients\u2019 ascites to the cytotoxic activity of autologous lymphocytes redirected by a bispecific anti-TRAIL-R2\/anti-CD3 antibody.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that ChoK\u03b1\/\n                      <jats:italic>CHKA<\/jats:italic>\n                      impairment, by restoring drug-induced or receptor-mediated cell death, could be a suitable therapeutic strategy to be used in combination with chemotherapeutics or immunomodulators to improve OC patients\u2019 outcome.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-020-01794-6","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T23:15:59Z","timestamp":1609715759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells"],"prefix":"10.1186","volume":"40","author":[{"given":"Andrea","family":"Rizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Figini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"De Cecco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egidio","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tomassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-6871","authenticated-orcid":false,"given":"Delia","family":"Mezzanzanica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"1794_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA A Cancer J Clin"},{"key":"1794_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353.","journal-title":"Lancet."},{"key":"1794_CR3","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene."},{"key":"1794_CR4","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-03-0537","volume":"10","author":"D Mezzanzanica","year":"2004","unstructured":"Mezzanzanica D, Balladore E, Turatti F, et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res. 2004;10:5202\u201314.","journal-title":"Clin Cancer Res"},{"key":"1794_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1158\/1535-7163.MCT-06-0357","volume":"6","author":"M Bagnoli","year":"2007","unstructured":"Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment. Mol Cancer Ther. 2007;6:762\u201372.","journal-title":"Mol Cancer Ther"},{"key":"1794_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1677\/ERC-08-0218","volume":"16","author":"M Bagnoli","year":"2009","unstructured":"Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, Galligioni E, Biganzoli E, Canevari S, Mezzanzanica D. C-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr Relat Cancer. 2009;16:443\u201353.","journal-title":"Endocr Relat Cancer"},{"key":"1794_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1359-6101(03)00029-7","volume":"14","author":"A Almasan","year":"2003","unstructured":"Almasan A, Ashkenazi A. Apo2L\/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003;14:337\u201348.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1794_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fonc.2015.00069","volume":"5","author":"R Trivedi","year":"2015","unstructured":"Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol. 2015;5:69.","journal-title":"Front Oncol"},{"key":"1794_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ygyno.2010.05.034","volume":"119","author":"KS Bevis","year":"2010","unstructured":"Bevis KS, Buchsbaum DJ, Straughn JM Jr. Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol. 2010;119:157\u201363.","journal-title":"Gynecol Oncol"},{"key":"1794_CR10","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3389\/fimmu.2019.02514","volume":"10","author":"A Satta","year":"2019","unstructured":"Satta A, Grazia G, Caroli F, et al. A bispecific antibody to link a TRAIL-based antitumor approach to immunotherapy. Front Immunol. 2019;10:2514.","journal-title":"Front Immunol"},{"key":"1794_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"1794_CR12","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1158\/1078-0432.CCR-14-2792","volume":"21","author":"E Strekalova","year":"2015","unstructured":"Strekalova E, Malin D, Good DM, Cryns VL. Methionine deprivation induces a targetable vulnerability in triple-negative breast cancer cells by enhancing TRAIL receptor-2 expression. Clin Cancer Res. 2015;21:2780\u201391.","journal-title":"Clin Cancer Res"},{"key":"1794_CR13","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1158\/0008-5472.CAN-04-0592","volume":"64","author":"DM Kokkinakis","year":"2004","unstructured":"Kokkinakis DM, Liu X, Chada S, Ahmed MM, Shareef MM, Singha UK, Yang S, Luo J. Modulation of gene expression in human central nervous system tumors under methionine deprivation-induced stress. Cancer Res. 2004;64:7513\u201325.","journal-title":"Cancer Res"},{"key":"1794_CR14","doi-asserted-by":"crossref","unstructured":"Yamamoto J, Miyake K, Han Q, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020.","DOI":"10.1016\/j.canlet.2020.07.034"},{"key":"1794_CR15","first-page":"3","volume":"8","author":"A Sreedhar","year":"2018","unstructured":"Sreedhar A, Zhao Y. Dysregulated metabolic enzymes and metabolic reprogramming in cancer cells. Biomed Rep. 2018;8:3\u201310.","journal-title":"Biomed Rep"},{"key":"1794_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","volume":"21","author":"P Ward","year":"2012","unstructured":"Ward P, Thompson C. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297\u2013308.","journal-title":"Cancer Cell"},{"key":"1794_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrc3162","volume":"11","author":"K Glunde","year":"2011","unstructured":"Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11:835\u201348.","journal-title":"Nat Rev Cancer"},{"key":"1794_CR18","doi-asserted-by":"publisher","first-page":"9369","DOI":"10.1158\/0008-5472.CAN-05-1146","volume":"65","author":"E Iorio","year":"2005","unstructured":"Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65:9369\u201376.","journal-title":"Cancer Res"},{"key":"1794_CR19","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/0008-5472.CAN-09-3833","volume":"70","author":"E Iorio","year":"2010","unstructured":"Iorio E, Ricci A, Bagnoli M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010;70:2126\u201335.","journal-title":"Cancer Res"},{"key":"1794_CR20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1074\/jbc.M708766200","volume":"283","author":"G Wu","year":"2008","unstructured":"Wu G, Aoyama C, Young SG, Vance DE. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem. 2008;283:1456\u201362.","journal-title":"J Biol Chem"},{"key":"1794_CR21","doi-asserted-by":"publisher","first-page":"11284","DOI":"10.1158\/0008-5472.CAN-07-2728","volume":"67","author":"N Mori","year":"2007","unstructured":"Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007;67:11284\u201390.","journal-title":"Cancer Res"},{"key":"1794_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fonc.2016.00153","volume":"6","author":"M Bagnoli","year":"2016","unstructured":"Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo F, Canevari S, Iorio E, Mezzanzanica D. Choline metabolism alteration: a focus on ovarian cancer. Front Oncol. 2016;6:153.","journal-title":"Front Oncol"},{"key":"1794_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/bjc.2013.729","volume":"110","author":"A Granata","year":"2014","unstructured":"Granata A, Nicoletti R, Tinaglia V, et al. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer. Br J Cancer. 2014;110:330\u201340.","journal-title":"Br J Cancer"},{"key":"1794_CR24","doi-asserted-by":"publisher","first-page":"11216","DOI":"10.18632\/oncotarget.3589","volume":"6","author":"A Granata","year":"2015","unstructured":"Granata A, Nicoletti R, Perego P, et al. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget. 2015;6:11216\u201330.","journal-title":"Oncotarget."},{"key":"1794_CR25","doi-asserted-by":"publisher","unstructured":"Rizzo A, Napoli A, Roggiani F, Tomassetti A, Bagnoli M, Mezzanzanica D. One-carbon metabolism: Biological players in epithelial ovarian cancer. Int J Mol Sci. 2018;19. https:\/\/doi.org\/10.3390\/ijms19072092.","DOI":"10.3390\/ijms19072092"},{"key":"1794_CR26","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/nar\/gng015","volume":"31","author":"RA Irizarry","year":"2003","unstructured":"Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.","journal-title":"Nucleic Acids Res"},{"key":"1794_CR27","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/annonc\/mdu173","volume":"25","author":"L De Cecco","year":"2014","unstructured":"De Cecco L, Bossi P, Locati L, Canevari S, Licitra L. Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor. Ann Oncol. 2014;25:1628\u201335.","journal-title":"Ann Oncol"},{"key":"1794_CR28","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1038\/sj.onc.1203839","volume":"19","author":"M Bagnoli","year":"2000","unstructured":"Bagnoli M, Tomassetti A, Figini M, Flati S, Dolo V, Canevari S, Miotti S. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene. 2000;19:4754\u201363.","journal-title":"Oncogene."},{"key":"1794_CR29","first-page":"1084","volume":"10","author":"A Satta","year":"2018","unstructured":"Satta A, Mezzanzanica D, Caroli F, et al. Design, selection and optimization of an anti-TRAIL-R2\/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs. 2018;10:1084\u201397.","journal-title":"MAbs."},{"key":"1794_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","volume":"25","author":"GS Ducker","year":"2017","unstructured":"Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab. 2017;25:27\u201342.","journal-title":"Cell Metab"},{"key":"1794_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0955-0674(99)80034-9","volume":"11","author":"A Ashkenazi","year":"1999","unstructured":"Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255\u201360.","journal-title":"Curr Opin Cell Biol"},{"key":"1794_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/35036052","volume":"1","author":"K Simons","year":"2000","unstructured":"Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000;1:31\u20139.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1794_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.277.5327.768","volume":"277","author":"T Gura","year":"1997","unstructured":"Gura T. How TRAIL kills cancer cells, but not normal cells. Science. 1997;277:768.","journal-title":"Science."},{"key":"1794_CR34","volume-title":"TRAIL of hope meeting resistance in cancer, trends Cancer","author":"D Deng","year":"2020","unstructured":"Deng D, Shah K. TRAIL of hope meeting resistance in cancer, trends Cancer; 2020."},{"key":"1794_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157\u201363.","journal-title":"Nat Med"},{"key":"1794_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1349-7006.2004.tb02181.x","volume":"95","author":"H Yagita","year":"2004","unstructured":"Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 2004;95:777\u201383.","journal-title":"Cancer Sci"},{"key":"1794_CR37","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1200\/JCO.2007.13.1011","volume":"25","author":"MJ Dyer","year":"2007","unstructured":"Dyer MJ, MacFarlane M, Cohen GM. Barriers to effective TRAIL-targeted therapy of malignancy. J Clin Oncol. 2007;25:4505\u20136.","journal-title":"J Clin Oncol"},{"key":"1794_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","volume":"12","author":"L Zhang","year":"2005","unstructured":"Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228\u201337.","journal-title":"Cancer Gene Ther"},{"key":"1794_CR39","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc.2017.28","volume":"17","author":"S von Karstedt","year":"2017","unstructured":"von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer. 2017;17:352\u201366.","journal-title":"Nat Rev Cancer"},{"key":"1794_CR40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature11743","volume":"493","author":"OD Maddocks","year":"2013","unstructured":"Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493:542\u20136.","journal-title":"Nature."},{"key":"1794_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/0006-291X(83)91218-4","volume":"117","author":"JO Mecham","year":"1983","unstructured":"Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun. 1983;117:429\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"1794_CR42","first-page":"643","volume":"6","author":"F Poirson-Bichat","year":"2000","unstructured":"Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B, Poupon MF. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res. 2000;6:643\u201353.","journal-title":"Clin Cancer Res"},{"key":"1794_CR43","first-page":"415","volume":"22","author":"S Lu","year":"2003","unstructured":"Lu S, Hoestje SM, Choo E, Epner DE. Induction of caspase-dependent and -independent apoptosis in response to methionine restriction. Int J Oncol. 2003;22:415\u201320.","journal-title":"Int J Oncol"},{"key":"1794_CR44","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1172\/JCI114784","volume":"86","author":"GB Mills","year":"1990","unstructured":"Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest. 1990;86:851\u20135.","journal-title":"J Clin Invest"},{"key":"1794_CR45","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"1794_CR46","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ijc.22840","volume":"121","author":"D Lane","year":"2007","unstructured":"Lane D, Robert V, Grondin R, Rancourt C, Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K\/akt pathway in human ovarian carcinoma cells. Int J Cancer. 2007;121:1227\u201337.","journal-title":"Int J Cancer"},{"key":"1794_CR47","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1038\/onc.2010.107","volume":"29","author":"D Lane","year":"2010","unstructured":"Lane D, Goncharenko-Khaider N, Rancourt C, Piche A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and akt activation. Oncogene. 2010;29:3519\u201331.","journal-title":"Oncogene."},{"key":"1794_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/2395-3977.196910","volume":"2","author":"J Lacal","year":"2016","unstructured":"Lacal J, Andera L. Choline kinase inhibitors synergize with TRAIL in the treatment of colorectal tumors and overcomes TRAIL resistance. Cancer Transl Med. 2016;2:163\u201374.","journal-title":"Cancer Transl Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-020-01794-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T23:17:58Z","timestamp":1609715878000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01794-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-01794-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,4]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written informed consent, and the study was approved by the Institutional Research Ethic Committee of Fondazione IRCCS Istituto Nazionale dei Tumori.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}